



MOREPEN



Date: 12/08/2024

To,
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
Symbol: MOREPENLAB

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001
Scrip Code: 500288

Ref: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Subject: Outcome of the meeting of the Board of Directors of Morepen Laboratories Limited ("company")

Dear Sir/ Ma'am,

Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform that the Board of Directors of the company in their meeting held today *i.e.*, Monday, 12th August, 2024 (*commenced at 8:30 A.M. and concluded at 9.45 A.M.*), have, *inter-alia*, considered and approved:

1. Un-audited standalone and consolidated financial results of the company for the quarter ended 30th June, 2024.

Pursuant to Regulation 33 of the SEBI Listing Regulations, a copy of the 'Results' along-with Limited Review Report of the Statutory Auditors of the company, are enclosed herewith.

2. Re-appointment of Mr. Praveen Kumar Dutt (DIN: 06712574) as an Independent Director for a second term of 5 consecutive years, effective from 13th August, 2024, subject to the approval of the members in the ensuing Annual General Meeting of the company.
3. Appointment of Mr. Ranjit Khattar (DIN: 00726997) as an Independent Director, for a term of 5 consecutive years, effective from 12th August, 2024, subject to the approval of the members in the ensuing Annual General Meeting of the company.
4. Promotion of Mr. Sandeep Kumar [General Manager - Plant Operations (Medipath)], being a Functional Head / Senior Management Personnel, to Vice President - Plant Operations (Medipath), Senior Management Personnel, with effect from 1st April 2024.

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com



MOREPEN



The relevant information pursuant SEBI Listing Regulations read along-with SEBI circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023, is enclosed herewith as Annexure.

You are requested to take note of the same in your records.

Thanking you,

Yours faithfully,

For Morepen Laboratories Limited

Vipul Kumar Srivastava
Company Secretary
F-12148

Encl. a/a.

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com



Annexure

Details as per SEBI Listing Regulations read with SEBI circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023;

S. no.	Particulars	Mr. Praveen Kumar Dutt	Mr. Ranjit Khattar
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment	Appointment
2.	Date of appointment/ cessation (as applicable) & term of appointment	13 th August 2024; Second term of 5 years.	12 th August 2024; A term of 5 year.
3.	Brief profile	Mr. Praveen Kumar Dutt is a fellow member of the Institute of Chartered Accountant of India (ICAI) having post qualification experience of around 30 years in the field of Direct Tax matters, FEMA, and International Taxation.	Mr. Ranjit Khattar is a fellow member of the Institute of Chartered Accountant of India (ICAI) having post qualification experience of around 35 years in the field of Accounts, Audits including Internal Audit, Taxation, Fundraising from Banks/ Financial Institutions and Private Equity funds.
4.	Disclosure of relationships between directors	Mr. Praveen Kumar Dutt is not related to any Director.	Mr. Ranjit Khattar is not related to any Director.

S. no.	Particulars	Mr. Sandeep Kumar
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	Promotion
2.	Date of appointment/ cessation (as applicable) & term of appointment	1 st April 2024
3.	Brief profile	Not applicable
4.	Disclosure of relationships between directors	Not applicable

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com

Morepen Laboratories Limited
CIN- L24231HP1984PLC006028
Statement of Unaudited Financial Results - Standalone
For the Quarter Ended 30th June, 2024

(Rs.in Lakhs, except per share data)

Sl.	Particulars	Quarter Ended		Year Ended	
		30.06.2024 (Unaudited)	31.03.2024 (Audited)	30.06.2023 (Unaudited)	31.03.2024 (Audited)
1.	Income				
	Income from operations (Net)	38564.32	39260.02	36910.29	153759.35
	Other Income	307.19	398.60	208.39	1256.57
	Total Income	38871.51	39658.62	37118.68	155015.92
2.	Expenditure				
	a) Cost of Material Consumed	23501.46	22026.28	20008.38	88330.68
	b) Purchase of stock - in - trade	580.68	232.93	3262.26	6184.38
	c) Changes in inventories of Finished goods, Work -in-progress and Stock-in-trade	(922.03)	1130.10	262.10	512.96
	d) Employee Benefits Expenses	3993.54	4016.61	4107.08	16027.88
	e) Finance Cost	104.42	72.77	28.27	350.94
	f) Depreciation and Amortization	359.02	668.84	489.27	2189.98
	g) Power and Fuel	927.23	1019.75	692.33	3408.91
	h) Travelling Expenses	370.87	478.03	400.88	1679.85
	i) Selling and Distribution Expenses	2615.92	1513.24	2767.60	9915.35
	j) Other Expenses	2635.62	3229.42	2929.28	11517.44
	Total Expenditure	34166.73	34387.97	34947.45	140118.37
3.	Profit before Tax (1-2)	4704.78	5270.65	2171.23	14897.55
4.	Tax Expense				
	Current Tax	1199.82	1318.33	586.23	3856.64
	Earlier Periods Tax	-	-	-	(9.04)
	Deffered Tax	-	(43.65)	-	(43.65)
	Total Tax	1199.82	1274.68	586.23	3803.95
5.	Net Profit for the period (3-4)	3504.96	3995.97	1585.00	11093.60
6.	Other Comprehensive Income (OCI)				
	Items that will not be reclassified to Profit & Loss	341.46	(298.31)	149.90	(270.60)
	Income Tax	85.91	(75.21)	40.47	(68.01)
	Other Comprehensive Income (Net of Tax)	255.55	(223.10)	109.43	(202.59)
	Total Comprehensive Income (5+6)	3760.51	3772.87	1694.43	10891.01
7.	Paid-up Equity Share Capital of Face Value of Rs.2/- each	10222.71	10222.71	10222.71	10222.71
8.	Other Equity				78679.72
9.	Earning Per Share (in Rs.)				
	- Basic & Diluted	0.69	0.78	0.31	2.17

Notes :

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on Aug 12, 2024. A Limited review of the same has been carried out by the Statutory Auditors.
- The company has successfully completed a Qualified Institutional Placement (QIP) for Rs. 200 crores on August 5, 2024 by issuing and allotting 3,67,84,991 new Equity shares to the investors. The capital base of company expanded by 6.71% from 51,11,68,708 to 54,79,53,699 Equity Shares of Rs. 2/- each.
- Figures for the quarter ended March 31,2024 are the balancing figures between audited figures in respect of the full financial year and the year to date figure up to the third quarter of the relevant financial year which were subjected to Limited Review by the Auditors.
- The Company is engaged in the Pharmaceutical Business Segment.

For and on behalf of the Board of Directors

Place : Gurugram, Haryana
Date : August 12, 2024



(Signature)

(Sushil Suri)
Chairman & Managing Director

S.P. Babuta and Associates

Chartered Accountants

#240, Sector 21-A, Chandigarh-160022, Tel: 91 172 2704943, 2713814, Email ID : spbabuta@hotmail.com, Website : www.babuta.com

Limited Review Report – Standalone Financial Results

**Review Report to
The Board of Directors
Morepen Laboratories Limited**

1. We have reviewed the accompanying statement of standalone financial results of Morepen Laboratories Limited (the "Company") for the quarter ended June 30, 2024 (the "Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.P. Babuta & Associates
Chartered Accountants
F. No.: 007657N

Sukhen
Pal Babuta

Digitally signed by
Sukhen Pal Babuta
Date: 2024.08.12
08:52:29 +05'30'

CA S. P. Babuta
Managing Partner
FCA, IP, DISA, CCA
GST Cert, Forensic Auditor
Membership No.: 086348

UDIN No.: 24086348BKGUTV5879

Dated: 12/08/2024
Place: Gurugram, Haryana

Morepen Laboratories Limited
CIN- L24231HP1984PLC006028
Statement of Unaudited Financial Results - Consolidated
For the Quarter Ended 30th June, 2024


(Rs.in Lakhs, except per share data)

Sl.	Particulars	Quarter Ended		Year Ended	
		30.06.2024	31.03.2024	30.06.2023	31.03.2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1.	Income				
	Income from operations (Net)	45521.57	42307.35	40103.62	169043.25
	Other Income	342.70	424.30	241.99	1397.08
	Total Income	45864.27	42731.65	40345.61	170440.33
2.	Expenditure				
	a) Cost of Material Consumed	23501.46	22026.28	20008.38	88330.68
	b) Purchase of stock - in - trade	5597.43	3008.46	5771.18	17700.48
	c) Changes in inventories of Finished goods, Work -in-progress and Stock-in-trade	(817.75)	617.65	329.15	211.33
	d) Employee Benefits Expenses	4795.52	4794.35	4340.86	18146.55
	e) Finance Cost	115.19	79.80	28.27	371.02
	f) Depreciation and Amortization	572.78	962.35	771.42	3346.95
	g) Power and Fuel	927.23	1019.75	692.33	3408.91
	h) Travelling Expenses	544.07	664.65	459.49	2186.09
	i) Selling and Distribution Expenses	2958.03	1851.36	2867.65	10997.89
	j) Other Expenses	2853.70	3486.82	3025.70	12198.86
	Total Expenditure	41047.66	38511.47	38294.43	156898.76
3.	Profit before Tax (1-2)	4816.61	4220.18	2051.18	13541.57
4.	Tax Expense				
	Current Tax	1199.82	1389.72	587.89	3932.22
	Earlier Periods Tax	-	0.01	-	(9.03)
	Deffered Tax	-	(43.65)	-	(43.65)
	Total Tax	1199.82	1346.08	587.89	3879.54
5.	Net Profit for the period (3-4)	3616.79	2874.10	1463.29	9662.03
6.	Share of Minority Interest in (Profit)/ Loss	-	46.04	(0.03)	46.04
7.	Net Profit after Minority Interest (5-6)	3616.79	2828.06	1463.32	9615.99
8.	Other Comprehensive Income/ (Loss) (OCI)				
	Items that will not be reclassified to Profit & Loss	343.06	(301.72)	141.73	(275.24)
	Income Tax	85.91	(75.21)	40.47	(68.01)
	Exchange differences on translation of foreign operations	-	23.05	-	23.05
	Other Comprehensive Income/ (Loss) (Net of Tax)	257.15	(203.46)	101.26	(184.18)
9.	Total Comprehensive Income (7+8)	3873.94	2624.60	1564.58	9431.81
10.	Paid-up Equity Share Capital of Face Value of Rs.2/- each	10222.71	10222.71	10222.71	10222.71
11.	Other Equity				74499.91
12.	Earning Per Share (in Rs.)				
	- Basic & Diluted	0.71	0.54	0.29	1.88

Notes :

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on Aug 12, 2024. A Limited review of the same has been carried out by the Statutory Auditors.
- The company has successfully completed a Qualified Institutional Placement (QIP) for Rs. 200 crores on August 5, 2024 by issuing and allotting 3,67,84,991 new Equity shares to the investors. The capital base of company expanded by 6.71% from 51,11,68,708 to 54,79,53,699 Equity Shares of Rs. 2/- each.
- Figures for the quarter ended March 31, 2024 are the balancing figures between audited figures in respect of the full financial year and the year to date figure up to the third quarter of the relevant financial year which were subjected to Limited Review by the Auditors.
- The Company is engaged in the Pharmaceutical Business Segment.

Place : Gurugram, Haryana
Date : August 12, 2024



(Signature)

(Sushil Suri)
Chairman & Managing Director

For and on behalf of the Board of Directors

S.P. Babuta and Associates

Chartered Accountants

#240, Sector 21-A, Chandigarh-160022, Tel: 91 172 2704943, 2713814, Email ID : sphabuta@hotmail.com, Website : www.babuta.com

Limited Review Report – Consolidated Financial Results

Review Report to The Board of Directors Morepen Laboratories Limited

1. We have reviewed the accompanying statement of consolidated financial results of Morepen Laboratories Limited (the “Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as the “Group”) for the quarter ended June 30, 2024 (the “Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. This Statement includes the results of the following Group entities:

- Morepen Laboratories Limited (the “Parent”)
- Dr. Morepen Limited (Indian Subsidiary)
- Total Care Limited (Indian Subsidiary)
- Morepen Devices Limited (Indian Subsidiary)
- Morepen Rx Ltd. (Indian Subsidiary)
- Morepen Bio Inc. (Foreign Subsidiary)



5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (“Ind AS”) specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of four subsidiaries i.e. Total Care Limited, Morepen Devices Limited, Morepen Rx Ltd. and Morepen Bio Inc., included in the statement, whose interim financial results reflect total comprehensive income of Rs.174.39 Lakhs (comprising of total revenue of Rs.8310.23 Lakhs and total expenses of Rs. 8133.31 Lakhs) for the quarter ended June 30, 2024. The interim financial results of these four subsidiaries have been reviewed by their auditors whose report has been furnished to us by the Parent’s management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

We have also not reviewed the financial results of above mentioned four subsidiaries and their financial results are based on management certified financial information.

Our conclusion on the Statement is not modified in respect of the above matter.

For S.P. Babuta & Associates
Chartered Accountants
F. No: 007657N

Digitally signed
by Sukhen Pal
Babuta
Date: 2024.08.12
08:54:42 +05'30'

Sukhen
Pal Babuta

CA S. P. Babuta
Managing Partner
FCA, IP, DISA, CCA
GST Cert, Forensic Auditor
Membership No.: 086348

UDIN: 24086348BKGUTW4155

Dated: 12/08/2024
Place: Gurugram, Haryana